Antibody imaging as biomarker in early cancer drug development and treatment Lamberts, Laetitia Elisabeth

Transcription

1 University of Groningen Antibody imaging as biomarker in early cancer drug development and treatment Lamberts, Laetitia Elisabeth IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2016 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Lamberts, L. E. (2016). Antibody imaging as biomarker in early cancer drug development and treatment [Groningen]: Rijksuniversiteit Groningen Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date:

2 ANTIBODY IMAGING AS BIOMARKER IN EARLY CANCER DRUG DEVELOPMENT AND TREATMENT Laetitia Elisabeth Lamberts

3 The research presented in this thesis was conducted at the Department of Medical Oncology of the University of Groningen. This research project was financially supported by Rijksuniversiteit Groningen, Universitair Medisch Centrum Groningen, Center for Translational Molecular Medicine (CTMM) project Mammary carcinoma Molecular Imaging for Diagnosis and Therapeutics (MAMMOTH), Genentech Inc. The printing of this thesis was financially supported by the Stichting Werkgroep Interne Oncologie, Rijksuniversiteit Groningen, Universitair Medisch Centrum Groningen, and Mr and Mrs Lamberts- de Vries, and is gratefully acknowledged. Lamberts, Laetitia Elisabeth Antibody imaging as biomarker in early cancer drug development and treatment Thesis, University of Groningen, The Netherlands 2016 L.E. Lamberts All rights are reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author. Cover: Dolinda Toepoel, Lay-out: Douwe Oppewal, Printed by: Ipskamp Drukkers, Enschede

4 Antibody imaging as biomarker in early cancer drug development and treatment Proefschrift ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen op gezag van de rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op maandag 23 mei om uur door Laetitia Elisabeth Lamberts geboren op 23 januari 1986 te Groningen

5 Promotores Prof. dr. E.G.E. de Vries Prof. dr. J.A. Gietema Copromotores Dr. C.P. Schröder Dr. A.H. Brouwers Beoordelingscommissie Prof. dr. H.J. Guchelaar Prof. dr. G.A. Langendijk Prof. dr. S. Sleijfer

6 Paranimfen C.N.H. Abheiden F. Bensch

7

8 Contents Chapter 1 General introduction 9 Chapter 2 Molecular imaging of tumors with radioactive labeled antibodies 17 from laboratory to the clinic. AACR education book 2012: Chapter 3 Antibody imaging in anticancer drug development. 25 J Clin Oncol 2015; 33: Chapter 4 Functional Genomic mrna Profiling of a large cancer data base 49 demonstrates mesothelin overexpression in a broad range of tumor types. Oncotarget 2015; 6: Chapter 5 Imaging the distribution of an antibody-drug conjugate constituent 63 targeting mesothelin with 89 Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. Oncotarget 2015; 6: Chapter 6 ImmunoPET with naked mesothelin antibody in pancreatic and 81 ovarian cancer patients before anti-mesothelin antibody-drug conjugate treatment. Clinical Cancer Research 2015; Nov 20 (Epub) Chapter 7 Phase I study of DMOT4039A, an antibody-drug conjugate 101 targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Molecular Cancer Therapeutics 2016; Jan 28 (Epub) Chapter 8 Molecular imaging as a tool to investigate heterogeneity of 119 advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial. Annals of Oncology 2015; Nov 23 (Epub) Chapter 9 Tumor specific uptake of fluorescent bevacizumab-irdye800cw: 135 a safe tool in image-guided surgery in patients with primary breast cancer. Submitted Chapter 10 Summary and future perspectives 161 Chapter 11 Nederlandse samenvatting (Summary in Dutch) 171 Dankwoord (Acknowledgements) 179 Publications 185

9